

Editorial commentaries

793 Predicting how many people might receive treatment with new therapies for Alzheimer's disease
B R Underwood

794 Implications for driving based on the risk of seizures after ischaemic stroke
N K Mishra

795 CIDP trials and tribulations
S Rinaldi

Neurodegeneration

796 Eligibility for anti-amyloid treatment: preparing for disease-modifying therapies for Alzheimer's disease
R Dobson, K Patterson, R Malik, U Mandal, H Asif, R Humphreys, M Payne, E O-Charonrat, L Huzzey, A Clare, K Green, M Morton, C Sohrabi, N Singh, A Pasupathy, M Patel, S Whiteman, K Maxmin, N Bass, B Gupta, C Cooper, C Marshall, R S Weil, C J Mummery

804 Patient-perceived progression in multiple system atrophy: natural history of quality of life
T Saulnier, M Fabbri, M Le Goff, C Helmer, A Pavy-Le Traon, W G Meissner, O Rascol, C Proust-Lima, A Foubert-Samier

812 Clinicrodiological and neuropathological evaluation of primary progressive aphasia
D Shir, N Corriveau-Lecavalier, C Bermudez Noguera, L Barnard, N T T Pham, H Botha, J R Duffy, H M Clark, R L Utianski, D S Knopman, R C Petersen, B F Boeve, M E Murray, A T Nguyen, R R Reichard, D W Dickson, G S Day, W K Kremers, N R Graff-Radford, D T Jones, M M Machulda, J A Fields, J L Whitwell, K A Josephs, J Graff-Radford

822 NfL reliability across laboratories, stage-dependent diagnostic performance and matrix comparability in genetic FTD: a large GENFI study
C Linnemann, C Wilke, D Mengel, H Zetterberg, C Heller, J Kuhle, A Bouzigues, L L Russell, P H Foster, E Ferry-Bolder, J C Van Swieten, L C Jiskoot, H Seelaar, F Moreno, B Borroni, R Sánchez-Valle, D Galimberti, R J Laforce, C Graff, M Masellis, M C Tartaglia, J B Rowe, E Finger, R Vandenberghe, A de Mendonca, C R Butler, A Gerhard, S Ducharme, I L E Ber, P Tiraboschi, I Santana, F Pasquier, J Levin, M Otto, S Sorbi, J D Rohrer, M Synofzik, GENFI

829 Peripheral hearing loss at age 70 predicts brain atrophy and associated cognitive change
T D Parker, C Hardy, S Keuss, W Coath, D M Cash, K Lu, J M Nicholas, S-N James, C Sudre, S Crutch, D-E Bamio, J D Warren, N C Fox, M Richards, J M Schott

Epilepsy

833 Implications for driving based on the risk of seizures after ischaemic stroke
K M Schubert, G Biciatto, L Sinke, L Abreira, E Santamarina, J Álvarez-Sabin, C Ferreira-Atuesta, M Katan, N Scherrer, R Terziev, N Döhler, B Erdélyi-Canavese, A Felbecker, P Siebel, M Winklehner, T J von Oertzen, J N Wagner, G L Gigli, A Nilo, F Janes, G Merlino, M Valente, M P Zafra-Sierra, L C Mayor-Romero, J Conrad, S Evers, P Lochner, F Roell, F Brigo, C Bentes, R Peralta, T Pinho e Melo, M R Keezer, J S Duncan, J W Sander, B Tettenborn, M Koepp, M Galovic

Neuromuscular

838 Prospective open-label trial with rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy not responding to conventional immune therapies
P E Doneddu, D Cocito, R Fazio, L Benedetti, E Peci, G Liberatore, Y M Falzone, F Germano, F Gallia, C Giannotta, C Lleixà, E Bianchi, E Nobile-Orazio

MORE CONTENTS ►


Editor Karen Furie (USA)
Deputy Editor Nick Ward (UK)
Associate Editors Aisling Carr (UK), Alan Carson (UK), Liz Coulthard (UK), Sofia Eriksson (UK), Ritsuko Hanajima (Japan), Bruce V Taylor (Australia), Peter Warnke (USA)
Commissioning Editor William Powers (USA)
Social Media Editor Hanna Kristiina Isotalu (UK)
Podcast Editor Saima Chaudhry (USA)
Editors, Practical Neurology Geraint Fuller (UK), Phil Smith (UK)
Editorial Office Journal of Neurology Neurosurgery & Psychiatry, BMJ Publishing Group Ltd, BMA House, Tavistock Square, London WC1H 9JR, UK. E: jnnp@bmj.com, X: @JNNP_BMJ, ISSN: 0022-3050 (print), ISSN: 1468-330X (online), Impact factor: 8.7

Disclaimer: The Editor of JNNP has been granted editorial freedom and JNNP is published in accordance with editorial guidelines issued by the World Association of Medical Editors and the Committee on Publication Ethics. JNNP is primarily intended for healthcare professionals and its content is for information only. The Journal is published without any guarantee as to its accuracy or completeness and any representations or warranties are expressly excluded to the fullest extent permitted by law. Readers are advised to independently verify any information on which they choose to rely. Acceptance of advertising by JNNP does not imply endorsement. BMJ Publishing Group Limited shall not be liable for any loss, injury or damage howsoever arising from JNNP (except for liability which cannot be legally excluded). Copyright: © 2024 BMJ Publishing Group Ltd. All rights reserved; no part of this publication may be reproduced in any form without permission. JNNP is published by BMJ Publishing Group Ltd, typeset by Exeter Premedia Services Private Ltd, Chennai, India and printed in the UK on acid-free paper from sustainable forests. Journal of Neurology Neurosurgery & Psychiatry ISSN 0022-3050 (USPS 2156) is published monthly by BMJ Publishing Group Ltd, BMA House, Tavistock Square, WC1H 9JR London. Airfreight and mailing in the USA by agent named World Container Inc, 150-15, 183rd Street, Jamaica, NY 11413, USA. Periodicals postage paid at Brooklyn, NY 11256. US Postmaster: Send address changes to Journal of Neurology Neurosurgery & Psychiatry, World Container Inc, 150-15, 183rd Street, Jamaica, NY 11413, USA. Subscription records are maintained at BMA House, Tavistock Square, WC1H 9JR London Air Business Ltd is acting as our mailing agent.


Editor's Choice, Patient's Choice, Open Access, Impact Commentaries series, Member since 2008, This journal is a member of and subscribes to the principles of the Committee on Publication Ethics http://publicationethics.org/



MCOs The online version of this article contains multiple choice questions hosted on BMJ Learning.

- 845** Efficacy, safety and tolerability of rozanolixizumab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a randomised, subject-blind, investigator-blind, placebo-controlled, phase 2a trial and open-label extension study
 OPEN ACCESS
L Querol, J De Sèze, T Dysgaard, T Levine, T H Rao, M Rivner, H-P Hartung, P Kiessling, S Shimizu, D Marmol, A Bozorg, A-O Colson, U Massow, F Efimov, CIDP01 Study Investigators


Multiple sclerosis

- 855** T cell activation markers CD38 and HLA-DR indicative of non-seroconversion in anti-CD20-treated patients with multiple sclerosis following SARS-CoV-2 mRNA vaccination
 OPEN ACCESS
N J M Verstegen, R R Hagen, C Kreher, L H Kuijper, J v den Dijssel, T Ashhurst, L Y L Kummer, V Palomares Cabeza, M Steenhuis, M C Duurland, R de Jongh, C E v der Schoot, V A L Konijn, E Mul, K Kedzierska, K P J van Dam, E W Stalman, L Boekel, G Wolbink, S W Tas, J Killestein, T Rispens, L Wieske, T W Kuipers, F Efimov, Z L E van Kempen, S M van Ham, A ten Brinke, C E van de Sandt, on behalf of T2B1 immunity against SARS-CoV-2 study group

Neuro-inflammation

- 865** Prevalence of autoimmune diseases in functional neurological disorder: influence of psychiatric comorbidities and biological sex
A Joseph, G Baslet, M A O'Neal, G Polich, I Gonsalvez, A N Christoforou, B A Dworetzky, P A Spagnolo
- 870** Validation of the international MOGAD panel proposed criteria: a single-centre US study
A G Filippatou, Y Said, H Chen, E S Vasileiou, G Ahmadi, E S Sotirchos

Neuropsychiatry

- 874** Pain and functional neurological disorder: a systematic review and meta-analysis
 OPEN ACCESS
M Steinruecke, I Mason, M Keen, L McWhirter, A J Carson, J Stone, I Hoeritzauer

PostScript

- 886** Letters